Antithrombotic PreTreatment and Invasive Strategies in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome.
Cyril CamaroPeter DammanPublished in: Journal of clinical medicine (2020)
In the current era, the antithrombotic treatment of patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) includes standard aspirin, and one of the potent P2Y12 inhibitors ticagrelor or prasugrel. The optimal timing of ticagrelor has not been adequately studied, while prasugrel is only recommended after coronary angiography prior to PCI. The invasive strategy, including indication and timing of angiography, depends on risk stratification and a mortality benefit has been shown in selected high-risk NSTE-ACS undergoing early (<24 h) intervention.
Keyphrases
- acute coronary syndrome
- percutaneous coronary intervention
- antiplatelet therapy
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute myocardial infarction
- coronary artery bypass grafting
- atrial fibrillation
- cardiovascular events
- low dose
- randomized controlled trial
- computed tomography
- optical coherence tomography
- coronary artery bypass
- coronary artery disease
- cardiovascular disease
- left ventricular
- type diabetes
- heart failure
- anti inflammatory drugs
- solid state